[ad_1]
There is an almost infinite amount of bacteria in the world, experts say. Some can do us good, others are responsible for diseases and epidemics. Among them, there is a group called superbugs, which are resistant to a very large number of drugs.
Bacterial resistance is considered one of the major threats to global health. According to the World Health Organization (WHO), about 700,000 people die each year from these superbugs. The prediction is that this number rises to 10 million deaths by 2050.
Also read: Ameba who "eats the brain "can be found in Brazil is Klebsiella pneumoniae producing carbapenemase (KPC). It has existed for a long time, but since the early 2000s, it has developed a resistance gene that makes it very difficult to treat. Today, KPC is resistant to approximately 95% of antibiotics or antimicrobials on the market.
It is against this bacteria that the National Agency for Sanitary Surveillance (Anvisa) approved a new drug. Torgena is the first antibiotic to arrive in the specific country for the fight against resistant bacteria. This is a combination of the antibiotic ceftazidime with avibactam, a molecule that gives the product a greater effectiveness on KPC and other multidrug-resistant bacteria.
The Medical Director of the Laboratory of Microbiology at USP Clinic das Clínicas, Flávia Rossi, explains that this superbug C is a problem that affects virtually every hospital in Brazil.
"She lives in a hospitable environment and has a very strong resistance. In order to avoid contaminating patients, it is necessary to collaborate with all staff, from hand hygiene and premises to a sufficient number of professionals to treat each patient and an agile diagnostic process, capable of to identify as quickly as possible the presence of this bacterium. "
According to the expert, KPC can cause any type of infection: urinary, in the skin, in the blood or in certain organs."
"Since KPC is resistant to antibiotics, it is very difficult to treat, so mortality is very high, especially in the most critically ill and immunocompromised patients, who have weakened immune systems, such as transplant patients. those who have HIV. "
For Flávia Rossi, the fact that Anvisa has approved the use of an antibiotic that proves its effectiveness against this superbugia will save many lives.
"CPK spreads in aggressive mu ito and having an effective drug against it means a new therapeutic possibility."
Do you want to avoid bacteria? Here are five mistakes people make in the bathroom:
Source link
